HUTCHMED (China) Limited (0013.HK)
HKD 23.0
(-0.22%)
HKD 23.0
(-0.22%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 86.13 Million USD | 269.66% |
| 2022 | 23.3 Million USD | -31.6% |
| 2021 | 34.06 Million USD | -4.6% |
| 2020 | 35.71 Million USD | 7.94% |
| 2019 | 33.08 Million USD | 23.73% |
| 2018 | 26.73 Million USD | -10.83% |
| 2017 | 29.98 Million USD | -35.91% |
| 2016 | 46.78 Million USD | -6.43% |
| 2015 | 50 Million USD | -6.02% |
| 2014 | 53.2 Million USD | 3.29% |
| 2013 | 51.5 Million USD | 35.1% |
| 2012 | 38.12 Million USD | 26.92% |
| 2011 | 30.03 Million USD | 22.6% |
| 2010 | 24.5 Million USD | 196.7% |
| 2009 | 8.25 Million USD | 8.57% |
| 2008 | 7.6 Million USD | 15.89% |
| 2007 | 6.56 Million USD | -7.76% |
| 2006 | 7.11 Million USD | -3.66% |
| 2005 | 7.38 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 85.7 Million USD | -0.5% |
| 2024 Q2 | 82.1 Million USD | 3.37% |
| 2023 Q2 | 40.14 Million USD | 0.0% |
| 2023 Q4 | 86.13 Million USD | 4.78% |
| 2023 Q3 | 82.2 Million USD | 104.76% |
| 2023 FY | 86.13 Million USD | 269.66% |
| 2023 Q1 | 40.14 Million USD | 72.3% |
| 2022 Q2 | 418 Thousand USD | 0.0% |
| 2022 Q3 | 23.29 Million USD | 5474.16% |
| 2022 FY | 23.3 Million USD | -31.6% |
| 2022 Q4 | 23.3 Million USD | 0.0% |
| 2022 Q1 | 418 Thousand USD | -98.77% |
| 2021 Q2 | 36.69 Million USD | -1.82% |
| 2021 Q1 | 37.37 Million USD | 4.65% |
| 2021 Q3 | 34.06 Million USD | -7.16% |
| 2021 FY | 34.06 Million USD | -4.6% |
| 2021 Q4 | 34.06 Million USD | 0.0% |
| 2020 Q3 | 33.5 Million USD | 2.42% |
| 2020 Q2 | 32.71 Million USD | 0.0% |
| 2020 FY | 35.71 Million USD | 7.94% |
| 2020 Q4 | 35.71 Million USD | 6.58% |
| 2020 Q1 | - USD | -100.0% |
| 2019 Q1 | 32.47 Million USD | 17.03% |
| 2019 FY | 33.08 Million USD | 23.73% |
| 2019 Q3 | 4.07 Million USD | -43.68% |
| 2019 Q2 | 7.24 Million USD | -77.7% |
| 2019 Q4 | 30.81 Million USD | 655.38% |
| 2018 FY | 26.73 Million USD | -10.83% |
| 2018 Q4 | 27.75 Million USD | 0.0% |
| 2018 Q2 | 26.69 Million USD | 0.0% |
| 2018 Q1 | - USD | -100.0% |
| 2017 FY | 29.98 Million USD | -35.91% |
| 2017 Q1 | 58.44 Million USD | 24.91% |
| 2017 Q4 | 29.98 Million USD | -7.93% |
| 2017 Q2 | 46.85 Million USD | -19.83% |
| 2017 Q3 | 32.57 Million USD | -30.48% |
| 2016 FY | 46.78 Million USD | -6.43% |
| 2016 Q1 | 56.94 Million USD | 13.88% |
| 2016 Q2 | 41.87 Million USD | -26.46% |
| 2016 Q3 | 57.15 Million USD | 36.48% |
| 2016 Q4 | 46.78 Million USD | -18.14% |
| 2015 Q3 | 46.79 Million USD | -7.59% |
| 2015 Q2 | 50.64 Million USD | -16.23% |
| 2015 Q4 | 50 Million USD | 6.85% |
| 2015 FY | 50 Million USD | -6.02% |
| 2015 Q1 | 60.45 Million USD | 13.63% |
| 2014 Q2 | 58.35 Million USD | -11.75% |
| 2014 FY | 53.2 Million USD | 3.29% |
| 2014 Q4 | 53.2 Million USD | 0.0% |
| 2014 Q1 | 66.12 Million USD | 28.37% |
| 2013 Q2 | 52.11 Million USD | 0.0% |
| 2013 FY | 51.5 Million USD | 35.1% |
| 2013 Q4 | 51.5 Million USD | -12.52% |
| 2013 Q3 | 58.88 Million USD | 13.0% |
| 2013 Q1 | 52.11 Million USD | 36.68% |
| 2012 Q2 | 28.79 Million USD | 0.0% |
| 2012 Q3 | - USD | -100.0% |
| 2012 FY | 38.12 Million USD | 26.92% |
| 2012 Q4 | 38.12 Million USD | 0.0% |
| 2011 FY | 30.03 Million USD | 22.6% |
| 2011 Q4 | 30.03 Million USD | 0.0% |
| 2010 Q4 | 24.5 Million USD | 0.0% |
| 2010 FY | 24.5 Million USD | 196.7% |
| 2010 Q2 | 16.76 Million USD | 0.0% |
| 2009 Q4 | 8.25 Million USD | 0.0% |
| 2009 FY | 8.25 Million USD | 8.57% |
| 2008 FY | 7.6 Million USD | 15.89% |
| 2007 FY | 6.56 Million USD | -7.76% |
| 2006 FY | 7.11 Million USD | -3.66% |
| 2005 FY | 7.38 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 6.8 Million HKD | -1164.773% |
| Grand Pharmaceutical Group Limited | 3.4 Billion HKD | 97.47% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | 28.469% |
| Wai Yuen Tong Medicine Holdings Limited | 460.94 Million HKD | 81.314% |
| Qianhai Health Holdings Limited | 487 Thousand HKD | -17586.037% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | 57.808% |
| Essex Bio-Technology Limited | 294.02 Million HKD | 70.706% |
| Tongfang Kontafarma Holdings Limited | 333.82 Million HKD | 74.199% |
| PuraPharm Corporation Limited | 424.77 Million HKD | 79.723% |
| SSY Group Limited | 3.37 Billion HKD | 97.447% |
| JBM (Healthcare) Limited | 133.4 Million HKD | 35.437% |
| Jacobson Pharma Corporation Limited | 749.37 Million HKD | 88.506% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 99.9% |